Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing

Human Molecular Genetics

Volumn 18, Issue 17, 2009, Pages 3266-3273

  Rodriguez Martin, Teresa ^a   Anthony, Karen ^a   Garcia Blanco, Mariano A ^b   Mansfield, S Gary ^c   Anderton, Brian H ^a   Gallo, Jean Marc ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c VIRxSYS Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN MAPT; TAU PROTEIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CHROMOSOME 17; CONTROLLED STUDY; ENHANCER REGION; EXON; FRONTOTEMPORAL DEMENTIA; GENE DELETION; GENE TARGETING; GENETIC TRANSFECTION; HYBRID GENE; INTRON; MUTATIONAL ANALYSIS; NONHUMAN; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; RNA SPLICING; SPLICEOSOME; SPLICING DEFECT; TRANS SPLICING;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; EXONS; HUMANS; MUTATION; SPLICEOSOMES; TAU PROTEINS; TAUOPATHIES; TRANS-SPLICING;

EID: 68749092850     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp264     Document Type: Article

References (49)

1. Ballatore, C., Lee, V.M. and Trojanowski, J.Q. (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci., 8, 663-672.
2. Gallo, J.-M., Noble, W. and Rodriguez Martin, T. (2007) RNA and protein-dependent mechanisms in tauopathies: Consequences for therapeutic strategies. Cell. Mol. Life Sci., 64, 1701-1714.
3. Williams, D.R. (2006) Tauopathies: Classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern. Med. J., 36, 652-660.
4. Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H.H., Pickering Brown, S., Chakraverty, S., Isaacs, A., Grover, A. et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393, 702-704.
5. Poorkaj, P., Bird, T.D., Wijsman, E., Nemens, E., Garruto, R.M., Anderson, L., Andreadis, A., Wiederholt, W.C., Raskind, M. and Schellenberg, G.D. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol, 43, 815-825.
6. Spillantini, M.G., Murrell, J.R., Goedert, M., Farlow, M.R., Klug, A. and Ghetti, B. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737-7741.
7. Brandt, R., Hundelt, M. and Shahani, N. (2005) Tau alteration and neuronal degeneration in tauopathies: Mechanisms and models. Biochim. Biophys. Acta., 1739, 331-354.
8. Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B.I., Geschwind, D.H., Bird, T.D., McKeel, D., Goate, A. et al. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science, 282, 1914-1917.
9. Connell, J.W., Rodriguez-Martin, T., Gibb, G.M., Khan, N.M., Grierson, A.J., Hanger, D.P., Revesz, T., Anderton, B.H. and Gallo, J.-M. (2005) Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Brain Res. Mol. Brain Res., 137, 104-109.
10. Dixit, R., Ross, J.L., Goldman, Y.E. and Holzbaur, E.L. (2008) Differential regulation of dynein and kinesin motor proteins by tau. Science, 319, 1086-1089.
11. Puttaraju, M., Jamison, S.F., Mansfield, S.G., Garcia-Blanco, M.A. and Mitchell, L.G. (1999) Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat. Biotechnol., 17, 246-252.
12. Mansfield, S.G., Clark, R.H., Puttaraju, M., Kole, J., Cohn, J.A., Mitchell, L.G. and Garcia-Blanco, M.A. (2003) 5′ exon replacement and repair by spliceosome-mediated RNA trans-splicing. RNA, 9 1290-1297.
13. Rodriguez-Martin, T., Garcia-Blanco, M.A., Mansfield, S.G., Grover, A.C., Hutton, M., Yu, Q., Zhou, J., Anderton, B.H. and Gallo, J.-M. (2005) Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: Implications for tauopathies. Proc. Natl Acad. Sci. USA, 102, 15659-15664.
14. Grover, A., Houlden, H., Baker, M., Adamson, J., Lewis, J., Prihar, G., Pickering-Brown, S., Duff, K. and Hutton, M. (1999) 5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J. Biol. Chem., 274, 15134-15143.
15. Donahue, C.P., Muratore, C., Wu, J.Y., Kosik, K.S. and Wolfe, M.S. (2006) Stabilization of the tau exon 10 stem loop alters pre-mRNA splicing. J. Biol. Chem., 281, 23302-23306.
16. D'Souza, I., Poorkaj, P., Hong, M., Nochlin, D., Lee, V.M., Bird, T.D. and Schellenberg, G.D. (1999) Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl Acad. Sci. USA, 96, 5598-5603.
17. Jiang, Z., Tang, H., Havlioglu, N., Zhang, X., Stamm, S., Yan, R. and Wu, J.Y. (2003) Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2β. J. Biol. Chem., 278, 18997-19007.
18. Yu, Q., Guo, J. and Zhou, J. (2004) A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10. J. Neurochem., 90, 164-172.
19. Jiang, Z., Cote, J., Kwon, J.M., Goate, A.M. and Wu, J.Y. (2000) Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17. Mol. Cell Biol., 20, 4036-4048.
20. Hasegawa, M., Smith, M.J., Iijima, M., Tabira, T. and Goedert, M. (1999) FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. FEBS Lett., 443, 93-96.
21. D'Souza, I. and Schellenberg, G.D. (2006) Arginine/serine-rich protein interaction domain-dependent modulation of a tau exon 10 splicing enhancer: Altered interactions and mechanisms for functionally antagonistic FTDP-17 mutations Δ280K and N279K. J. Biol. Chem., 281, 2460-2469.
22. van Swieten, J.C., Bronner, I.F., Azmani, A., Severijnen, L.A., Kamphorst, W., Ravid, R., Rizzu, P., Willemsen, R. and Heutink, P. (2007) The ΔK280 mutation in MAP tau favors exon 10 skipping in vivo. J. Neuropathol. Exp. Neurol., 66, 17-25.
23. Momeni, P., Pittman, A., Lashley, T., Vandrovcova, J., Malzer, E., Luk, C., Hulette, C., Lees, A., Revesz, T., Hardy, J. et al. (2009) Clinical and pathological features of an Alzheimer's disease patient with the MAPT ΔK280 mutation. Neurobiol. Aging, 30, 388-393.
24. Conrad, C., Zhu, J., Conrad, C., Schoenfeld, D., Fang, Z., Ingelsson, M., Stamm, S., Church, G. and Hyman, B.T. (2007) Single molecule profiling of tau gene expression in Alzheimer's disease. J. Neurochem., 103, 1228-1236.
25. Caffrey, T.M., Joachim, C., Paracchini, S., Esiri, M.M. and Wade-Martins, R. (2006) Haplotype-specific expression of exon 10 at the human MAPT locus. Hum. Mol. Genet., 15, 3529-3537.
26. Myers, A.J., Pittman, A.M., Zhao, A.S., Rohrer, K., Kaleem, M., Marlowe, L., Lees, A., Leung, D., McKeith, I.G., Perry, R.H. et al. (2006) The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol. Dis., 25, 561-570.
27. Donahue, C.P., Ni, J., Rozners, E., Glicksman, M.A. and Wolfe, M.S. (2007) Identification of tau stem loop RNA stabilizers. J. Biomol. Screen., 12, 789-799.
28. Stoilov, P., Lin, C.H., Damoiseaux, R., Nikolic, J. and Black, D.L. (2008) A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc. Natl Acad. Sci. USA, 105, 11218-11223.
29. Wood, M., Yin, H. and McClorey, G. (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS. Genet., 3, e109.
30. Garcia-Blanco, M.A. (2003) Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing. J. Clin. Invest., 112 474-480.
31. Mansfield, S.G., Chao, H. and Walsh, C.E. (2004) RNA repair using spliceosome-mediated RNA trans-splicing. Trends Mol. Med., 10, 263-268.
32. Yang, Y. and Walsh, C.E. (2005) Spliceosome-mediated RNA trans splicing. Mol. Ther., 12, 1006-1012.
33. Mitchell, L.G. and McGarrity, G.J. (2005) Gene therapy progress and prospects: Reprograming gene expression by trans-splicing. Gene Ther. 12, 1477-1485.
34. Kierlin-Duncan, M.N. and Sullenger, B.A. (2007) Using 5′-PTMs to repair mutant β-globin transcripts. RNA, 13, 1317-1327.
35. Wally, V., Klausegger, A., Koller, U., Lochmuller, H., Krause, S., Wiche, G., Mitchell, L.G., Hintner, H. and Bauer, J.W. (2008) 5′ trans-splicing repair of the PLEC1 gene. J. Invest Dermatol., 128, 568-574.
36. Zayed, H., Xia, L., Yerich, A., Yant, S.R., Kay, M.A., Puttaraju, M., McGarrity, G.J., Wiest, D.L., McIvor, R.S., Tolar, J. et al. (2007) Correction of DNA protein kinase deficiency by spliceosome-mediated RNA trans-splicing and Sleeping Beauty transposon delivery. Mol. Ther., 15, 1273-1279.
37. Coady, T.H., Shababi, M., Tullis, G.E. and Lorson, C.L. (2007) Restoration of SMN function: Delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol. Ther., 15, 1471-1478.
38. Coady, T.H., Baughan, T.D., Shababi, M., Passini, M.A. and Lorson, C.L. (2008) Development of a single vector system that enhances trans splicing of SMN2 transcripts. PLoS. ONE., 3, e3468.
39. Chen, H.Y., Kathirvel, P., Yee, W.C. and Lai, P.S. (2009) Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans splicing. Gene Ther., 16, 211-217.
40. Azzouz, M., Kingsman, S.M. and Mazarakis, N.D. (2004) Lentiviral vectors for treating and modeling human CNS disorders. J. Gene Med., 6 951-962.
41. Wong, L.F., Azzouz, M., Walmsley, L.E., Askham, Z., Wilkes, F.J., Mitrophanous, K.A., Kingsman, S.M. and Mazarakis, N.D. (2004) Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther., 9, 101-111.
42. Chao, H., Mansfield, S.G., Bartel, R.C., Hiriyanna, S., Mitchell, L.G., Garcia-Blanco, M.A. and Walsh, C.E. (2003) Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat. Med., 9, 1015-1019.
43. Tahara, M., Pergolizzi, R.G., Kobayashi, H., Krause, A., Luettich, K., Lesser, M.L. and Crystal, R.G. (2004) Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat. Med., 10, 835-841.
44. Liu, X., Luo, M., Zhang, L.N., Yan, Z., Zak, R., Ding, W., Mansfield, S.G., Mitchell, L.G. and Engelhardt, J.F. (2005) Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum. Gene Ther., 16, 1116-1123.
45. Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M.W., Cowan, C., Hochedlinger, K. and Daley, G.Q. (2008) Disease-specific induced pluripotent stem cells. Cell, 134, 877-886.
46. Faustino, N.A. and Cooper, T.A. (2003) Pre-mRNA splicing and human disease. Genes Dev., 17, 419-437.
47. Garcia-Blanco, M.A., Baraniak, A.P. and Lasda, E.L. (2004) Alternative splicing in disease and therapy. Nat. Biotechnol., 22, 535-546.
48. Gallo, J.-M., Jin, P., Thornton, C.A., Lin, H., Robertson, J., D'Souza, I. and Schlaepfer, W.W. (2005) The role of RNA and RNA processing in neurodegeneration. J. Neurosci., 25, 10372-10375.
49. Licatalosi, D.D. and Darnell, R.B. (2006) Splicing regulation in neurologic disease. Neuron, 52, 93-101.